A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Sponsor
Genentech, Inc.
Study ID
NCT00851136
Phase
PHASE1
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    Intravenous repeating dose
  • FOLFOX — DRUG
    Intravenous repeating dose
  • PRO95780 — DRUG
    Intravenous repeating dose

Study Details

This will be a multicenter, open-label study enrolling a total of up to 23 patients.

Key Dates

First listed
Feb 25, 2009
Start date
May 31, 2009
Status verified
Dec 2022
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1

Primary Outcome Measure

Incidence and nature of dose-limiting toxicities [ Time Frame: Length and study ]

Related Studies